Recent Advances in Inflammation & Allergy Drug Discovery最新文献_第10页

IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome. IL-6、IL-1β 和 MDA 与急性冠状动脉综合征患者心肌梗死溶栓治疗（TIMI）风险评分的相关性。

IF 1.1

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2022-01-01 DOI: 10.2174/2772270816666220211091231

Marcus V de Paula da Silva, Pedro Henrique Villar-Delfino, José A Nogueira-Machado, Caroline M O Volpe

{"title":"IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome.","authors":"Marcus V de Paula da Silva, Pedro Henrique Villar-Delfino, José A Nogueira-Machado, Caroline M O Volpe","doi":"10.2174/2772270816666220211091231","DOIUrl":"10.2174/2772270816666220211091231","url":null,"abstract":"Background: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification.Objective: This study aimed at determining the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic value to the TIMI risk score.Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS (n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset.Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients.Conclusion: These data suggested the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"71-79"},"PeriodicalIF":1.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39775573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3β: A Putative Target to Combat Mortality in Patients with COVID-19. 天然酚类化合物与GSK-3β的分子对接和动力学模拟:抗COVID-19患者死亡率的推定靶点

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2021-09-16 DOI: 10.2174/1872213x14666210916161447

Z. Khamverdi, Z. Mohamadi, Amir Taherkhani

{"title":"Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3β: A Putative Target to Combat Mortality in Patients with COVID-19.","authors":"Z. Khamverdi, Z. Mohamadi, Amir Taherkhani","doi":"10.2174/1872213x14666210916161447","DOIUrl":"https://doi.org/10.2174/1872213x14666210916161447","url":null,"abstract":"OBJECTIVE\u0000In this study, molecular docking analysis was performed to evaluate the binding affinity of 52 plant-based phenolics with the GSK-3β active sites. Moreover, Molecular Dynamics (MD) simulation was conducted to investigate the stability of interactions between the topranked phenolics and residues within the GSK-3β active sites.\u0000\u0000\u0000METHODS\u0000Molecular docking and MD simulations were performed using AutoDock and Discovery Studio Client software, respectively. Thereafter, pharmacokinetic and toxicological properties of top inhibitors were predicted using bioinformatics web tools. This study aimed to identify the most effective amino acids involved in the inhibition of GSK-3β based on the most stabilizing interactions between the residues and compounds, and also by considering the degree centrality in the ligand- amino acid interaction network for GSK-3β.\u0000\u0000\u0000RESULTS\u0000It was observed that procyanidin and amentoflavone could bind to the GSK-3β active sites at the picomolar (pM) scale as well as the binding affinity of ΔG binding < -13 kcal/mol, while the inhibition constant for theaflavin 3'-gallate, procyanidin B4, and rutin was calculated at the nanomolar (nM) scale, suggesting that these phenolic compounds can be considered as potential effective GSK-3β inhibitors. Furthermore, Val70, Ala83, Val135, and Tyr134 were found to be the most important amino acids involved in the inhibition of GSK-3β.\u0000\u0000\u0000CONCLUSION\u0000The results of the current study may be useful in the prevention of several human disorders, including COVID-19, cancers, Alzheimer's disease, diabetes mellitus, and cardiovascular diseases. However, wet-lab experiments need to be performed in the future.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"41 1","pages":"16-34"},"PeriodicalIF":0.4,"publicationDate":"2021-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86996995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Meet the Regional Editor 见见地区编辑

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2021-05-01 DOI: 10.2174/277227081501220210105335

K. Dhama

引用次数: 0

Development of Effective and Safe Analgesic and Anti-Inflammatory Drugs: Harnessing Natural Substances for Clinical Solutions. 有效和安全的镇痛和抗炎药物的开发:利用天然物质为临床解决方案。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2021-05-01 DOI: 10.2174/277227081501220210144154

S. Fiorucci

引用次数: 0